Sight Sciences, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $460.9M
- Price
- $8.47
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.04%
- Volume
- 464.3K
About
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.
Quick stats
Shares outstanding54.4M
Computed float54.4M
Float / shares100.0%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001531177
AI Summary
AI-generated1/16
majorbullishfda approval
TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease
Sight Sciences announced that the FDA updated the Indications for Use for its TearCare System, making it the first and only treatment indicated to improve meibomian gland function in adult patients with evaporative dry eye disease due to MGD.
This label expansion establishes a clinically meaningful endpoint focused on gland function rather than just symptom management, reinforcing the importance of addressing the underlying cause of dry eye disease.
CEO Paul Badawi described the update as a landmark moment for the company and the dry eye category, highlighting the commitment to interventional technologies.